Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PROTEOMICS -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (279)	5/8/2001 7:02:17 PM
From: keokalani'nui	Respond to of 539

MDS-P gets a new director. Tuesday May 8, 3:20 pm Eastern Time Press Release MDS Proteomics Expands Its Board of Directors Dr. Frank Lee, 20-year Biotech Industry Veteran Joins Functional Proteomics Company TORONTO--(BW HealthWire)--May 8, 2001--MDS Proteomics, an international biotechnology company focused on functional proteomics, today announced the appointment of Frank Lee, Ph.D. to its board of directors. Dr. Lee has nearly 20 years of expertise in molecular biology, biochemistry and cancer research and has significant experience in building a product development company. ``We are extremely excited to welcome Dr. Lee to our board of directors. Few can match his breadth of knowledge, experience and leadership in technology development and integration in genomics and biotechnology,'' said Frank Gleeson, president and chief executive officer of MDS Proteomics. ``Dr. Lee's prominent role as a builder of one of the industry's elite companies will be a great asset to MDS Proteomics in our mission to build a functional bridge from genomic information to drug discovery.'' Dr. Lee is currently the president and chief executive officer of engeneOS, Inc., a Boston-based company developing novel technologies to enable the design and construction of new types of programmable biomolecular machines for a wide range of commercial applications. Prior to joining engeneOS, Dr. Lee spent seven years at Millennium Pharmaceuticals, serving most recently as chief technology officer, leading the company's genomics research and discovery group, gaining expertise in the management of strategic relationships with numerous pharmaceutical companies. Lee also garnered substantial experience as the director of molecular biology at DNAX Research Institute of Molecular and Cellular biology where he played a key role in advancing its cutting-edge technologies in molecular biology and immunology. ``Joining MDS Proteomics' board was a careful, yet easy decision, as they have assembled some of the world's most prominent scientific minds and developed an unparalleled technology,'' said Dr. Lee. ``MDS Proteomics is positioned to play a significant role in the development of next generation medicines.'' Dr. Lee earned his Ph.D. from Stanford University, conducted his postdoctoral research at Stanford University School of Medicine (Department of Pharmacology) and was a senior fellow of the American Cancer Society. Additionally, Dr. Lee conducted postdoctoral research at the Massachusetts Institute of Technology Center for Cancer Research as a fellow of the Helen Hay Whitney Foundation. Dr. Lee has authored nearly 100 scientific papers.